Clinique Teissier
- Address
- 118 Désandrouin, 59300 Valenciennes, France
Clinique Teissier - Advanced Lung Cancer Research Center
Clinique Teissier is a specialized oncology research center dedicated to advancing treatment strategies for patients with non-small cell lung cancer. The center focuses on cutting-edge therapeutic approaches combining immunotherapy, targeted therapy, and radiation techniques to improve outcomes for patients with locally advanced disease.
- Stage III non-small cell lung cancer treatment optimization
- Concurrent chemoradiation therapy with immunotherapy integration
- Combination strategies using pembrolizumab and PARP inhibitors
The research team at Clinique Teissier is actively investigating novel treatment combinations, including pembrolizumab with concurrent chemoradiation followed by maintenance therapy with or without olaparib. Their clinical trials compare progression-free survival and overall survival outcomes against standard-of-care durvalumab-based regimens, utilizing RECIST 1.1 criteria and blinded independent central review for rigorous assessment of therapeutic efficacy in locally advanced lung cancer patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinique Teissier
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Evaluation of Pembrolizumab and Olaparib with Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Jun 2020 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 1 | Unknown | 2020-06-09 | 2020-06-09 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.